The Mell Lab runs multiple different projects crossing various disciplines, including collaborations with investigators in radiochemistry, virology, immunology, and pathology. A major focus has been focused on novel methods to study radiation damage to the immune system in patients receiving chemoradiotherapy, a major barrier to optimal treatment delivery.  Another focus is on the study radiation in combination with immunotherapy, particularly oncolytic viruses and PD-1:PD-L1 checkpoint inhibitors for the treatment of advanced head and neck cancer.

Mell Lab researchers also investigate approaches to improve the efficiency of clinical trials conducted in patients at risk for competing events, including the development of novel statistical approaches to better stratify patients reducing the incidence of competing events that tend to reduce statistical power.